Back

GIPC1 intermediate-length repeat expansion in amyotrophic lateral sclerosis

Muto, K.; Tachibana, K.; Miyamoto, R.; Kuwano, Y.; Kihara, N.; Yamazaki, H.; Osaki, Y.; Banzai, S.; Ueno, H.; Fukumoto, T.; Kamada, M.; Keyoumu, N.; Matsui, N.; Fujita, K.; Nakamori, M.; Yamazaki, Y.; Maruyama, H.; Izumi, Y.; Morino, H.

2025-05-23 neurology
10.1101/2025.05.22.25328088
Show abstract

Repeat expansion diseases, particularly those involving GC-rich motifs, have been increasingly recognized as contributors to neurological and neuromuscular disorders. Amyotrophic lateral sclerosis (ALS) has been linked to several such expansions, including intermediate-length repeats in genes implicated in oculopharyngodistal myopathy (OPDM). To investigate the possible involvement of CGG repeat expansions in ALS, 424 ALS patients and 312 controls of Japanese descent were screened for expansions in five genes associated with repeat expansion disorders, namely GIPC1, RILPL1, FMR1, AFF2, and NUTM2BAS1. Repeat-primed PCR and fragment analysis revealed that four ALS patients exhibited abnormal CGG expansions in GIPC1 (33-55 repeats), whereas two control individuals harbored expanded alleles (67 and 83 repeats). No expansions in the other genes were detected. Long-read sequencing confirmed repeat sizes and showed sequence instability. Histopathological analysis of ALS patients with GIPC1 expansion demonstrated classical ALS pathology, including phosphorylated TDP-43-positive inclusions. RNA fluorescence in situ hybridization revealed nuclear foci containing GIPC1 repeat RNA exclusively in ALS patients with GIPC1 expansions, suggesting RNA-mediated toxicity. These findings indicate that a subset of ALS patients present with intermediate CGG expansions in GIPC1, which may represent a novel pathogenic mechanism analogous to other noncoding repeat disorders. Given that GIPC1 full expansions are associated with OPDM, these results support the hypothesis of a pathological continuum between neurodegeneration and myopathy driven by repeat length and sequence context. Nonetheless, further investigations into the potential of GIPC1 CGG expansions as genetic risk factors or modifiers in ALS are warranted.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Brain
based on 69 papers
Top 1%
10.3%
2
Movement Disorders
based on 49 papers
Top 1%
7.6%
3
Journal of Neurology, Neurosurgery & Psychiatry
based on 26 papers
Top 0.3%
7.6%
4
Acta Neuropathologica
based on 11 papers
Top 0.1%
6.4%
5
PLOS ONE
based on 1737 papers
Top 64%
5.9%
6
Acta Neuropathologica Communications
based on 10 papers
Top 0.1%
5.9%
7
Annals of Neurology
based on 43 papers
Top 0.7%
4.7%
8
Annals of Clinical and Translational Neurology
based on 22 papers
Top 0.6%
4.5%
50% of probability mass above
9
Scientific Reports
based on 701 papers
Top 54%
2.8%
10
Neurology
based on 38 papers
Top 3%
2.8%
11
Journal of Neurology
based on 22 papers
Top 1%
2.8%
12
Brain Communications
based on 79 papers
Top 4%
2.5%
13
Nature Communications
based on 483 papers
Top 25%
2.5%
14
Parkinsonism & Related Disorders
based on 16 papers
Top 1%
2.5%
15
EMBO Molecular Medicine
based on 15 papers
Top 0.5%
1.8%
16
European Journal of Neurology
based on 20 papers
Top 2%
1.3%
17
eLife
based on 262 papers
Top 21%
1.3%
18
EBioMedicine
based on 21 papers
Top 1.0%
1.2%
19
Frontiers in Neurology
based on 74 papers
Top 10%
1.2%
20
eBioMedicine
based on 82 papers
Top 6%
0.8%
21
npj Parkinson's Disease
based on 35 papers
Top 2%
0.8%
22
Neurobiology of Disease
based on 12 papers
Top 1%
0.8%
23
Multiple Sclerosis and Related Disorders
based on 14 papers
Top 1%
0.8%
24
Alzheimer's & Dementia
based on 84 papers
Top 5%
0.8%
25
Neurobiology of Aging
based on 29 papers
Top 3%
0.8%
26
Proceedings of the National Academy of Sciences
based on 100 papers
Top 15%
0.7%
27
Med
based on 26 papers
Top 2%
0.7%
28
JCI Insight
based on 63 papers
Top 6%
0.7%
29
Orphanet Journal of Rare Diseases
based on 15 papers
Top 2%
0.7%